CagriSema misses noninferiority vs tirzepatide in REDEFINE 4; Novo Nordisk shares fall 15% iPharmaCenter Presented at the ADA 85th Scientific Sessions: In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine Switching to Tirzepatide 5 mg From Glucagon Like Peptide 1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment Endocrine Practice Cagrilintide Combined with Semaglutide: A New Approach for Treatment of Obesity and Type 2 Diabetes ClinicSearch Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination